Leveraging PSMA PET Imaging in Posttreatment Response Assessment: Evolving Practices and Data Insights
Panelists discuss how PSMA PET imaging is increasingly utilized to assess treatment response in prostate cancer, offering superior accuracy over PSA monitoring alone. Incorporating PSMA PET into clinical practice involves considering factors such as timing post treatment and the specific clinical scenario. For instance, studies have demonstrated that PSMA PET/CT can detect intraprostatic and metastatic lesions even at very low PSA levels during treatment monitoring.
Video content above is prompted by the following:
- Briefly outline the evolving role of PSMA PET imaging in assessing for posttreatment response and how you incorporate it in your practice.
- What is your timing protocol for postradiation PSMA PET imaging?
- Do you routinely use PSMA PET for posttreatment response assessment?
- What value may PSMA-PET posttreatment imaging offer compared with PSA monitoring alone?
- What do available data demonstrate, and how do these findings inform your decisions in this setting?
- 18F PSMA-1007 PET/CT vs PSA (Kleiburg et al. Eur J Rad. 2024)
- 68GaPSMA-11 (Esen et al. J Clin Oncol. 2023.)
- 68Ga-PSMA or 18F-DCFPyL-PSMA (Sutera et al. Adv Rad Onc. 2024)
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
